Traws Pharma (TRAW) & Its Rivals Head-To-Head Review

Traws Pharma (NASDAQ:TRAW) is one of 980 publicly-traded companies in the “Pharmaceutical preparations” industry, but how does it compare to its rivals? We will compare Traws Pharma to related companies based on the strength of its valuation, risk, earnings, profitability, analyst recommendations, dividends and institutional ownership.

Analyst Ratings

This is a breakdown of current ratings and price targets for Traws Pharma and its rivals, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Traws Pharma	0	0	0	0	N/A
Traws Pharma Competitors	7109	19440	44834	1058	2.55

As a group, “Pharmaceutical preparations” companies have a potential upside of 57.75%. Given Traws Pharma’s rivals higher possible upside, analysts clearly believe Traws Pharma has less favorable growth aspects than its rivals.

Insider and Institutional Ownership

7.9% of Traws Pharma shares are owned by institutional investors. Comparatively, 44.1% of shares of all “Pharmaceutical preparations” companies are owned by institutional investors. 3.3% of Traws Pharma shares are owned by insiders. Comparatively, 14.1% of shares of all “Pharmaceutical preparations” companies are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Volatility & Risk

Traws Pharma has a beta of 1.37, indicating that its stock price is 37% more volatile than the S&P 500. Comparatively, Traws Pharma’s rivals have a beta of 0.89, indicating that their average stock price is 11% less volatile than the S&P 500.

Earnings and Valuation

This table compares Traws Pharma and its rivals top-line revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Traws Pharma	$226,000.00	-$18.95 million	-5.59
Traws Pharma Competitors	$2.06 billion	$154.42 million	-4.32

Traws Pharma’s rivals have higher revenue and earnings than Traws Pharma. Traws Pharma is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.

Profitability

This table compares Traws Pharma and its rivals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Traws Pharma	-60,641.14%	-144.95%	-633.17%
Traws Pharma Competitors	-3,723.31%	-264.04%	-31.39%

Summary

Traws Pharma rivals beat Traws Pharma on 8 of the 10 factors compared.

Traws Pharma Company Profile

Traws Pharma, Inc., a clinical stage biopharmaceutical company, focuses on developing small molecule oral product candidates for respiratory viral diseases and cancer. The company is developing investigational novel therapies for influenza and COVID19 that are designed to address treatment resistance, such as TRX01 (travatrelvir), a Mpro/3CL inhibitor in development for the treatment of COVID19; and TRX100 (viroxavir), an endonuclease inhibitor in development for the treatment of pandemic influenza. It is also developing narazaciclib, a multi-kinase CDK4/6 inhibitor, which is in Phase 1/2 clinical trials in patients with cancer, with or without co-administration of letrozole to define the recommended phase 2 dose for further development in endometrial cancer; and oral rigosertib, which is administered alone or in combination for investigation in various cancers. The company was formerly known as Onconova Therapeutics, Inc. and changed its name to Traws Pharma, Inc. in April 2024. Traws Pharma, Inc. was incorporated in 1998 and is headquartered in Newtown, Pennsylvania.